Simultaneous quantitation of nicorandil and its denitrated metabolite in plasma by LC-MS/MS: Application for a pharmacokinetic study

Journal of Mass Spectrometry

Volumn 46, Issue 11, 2011, Pages 1125-1130

  César, Isabela Costa ^a   Bastos, Leandro Francisco Silva ^a   Godin, Adriana Martins ^a   De Matos Coelho, Márcio ^a   Araujo, Débora Pereira ^a   De Fátima, Ângelo ^a   Guidine, Patrícia Alves Maia ^a   Pianetti, Gerson Antônio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

denitrated metabolite; LC ESI MS MS; nicorandil; pharmacokinetics; plasma

Indexed keywords

AQUEOUS AMMONIUM; CALIBRATION CURVES; CHROMATOGRAPHIC SEPARATIONS; INTERNAL STANDARDS; ISOCRATIC MOBILE PHASE; LC-ESI-MS/MS; LC-MS/MS; LIQUID-LIQUID EXTRACTION; MATRIX EFFECTS; NICORANDIL; PHARMACOKINETIC STUDIES; RAT PLASMA; RELATIVE STANDARD DEVIATIONS; SELECTED REACTION MONITORING; TANDEM MASS SPECTROMETRY; VALIDATED METHODS;

AMIDES; AMMONIUM COMPOUNDS; BIOMOLECULES; CHROMATOGRAPHY; ELECTROSPRAY IONIZATION; FORMIC ACID; HIGH PRESSURE LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; METABOLITES; METHANOL; PHARMACOKINETICS; PLASMAS; SOLVENT EXTRACTION;

METABOLISM;

AMMONIUM ACETATE; DRUG METABOLITE; FORMIC ACID; N (2 HYDROXYETHYL) NICOTINAMIDE; NICORANDIL; PROCAINAMIDE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL TISSUE; ARTICLE; CALIBRATION; CONTROLLED STUDY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMATOGRAPHY, LIQUID; FEMALE; MALE; NIACINAMIDE; NICORANDIL; PROCAINAMIDE; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 82455219371     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1998     Document Type: Article

References (16)

1. K. Fox, M. A. A. Garcia, D. Ardissino, P. Buszman, P. G. Camici, F. Crea, C. Daly, G. De Backer, P. Hjemdahl, J. Lopez-Sendon, J. Marco, J. Morais, J. Pepper, U. Sechtem, M. Simoons, K. Thygesen,. Guidelines on the management of stable angina pectoris: executive summary. Eur. Heart J. 2006, 27, 1341.
2. Sociedade Brasileira de Cardiologia. VI Diretrizes Brasileiras de Hipertensão. Rev. Bras. Hipertens. 2010, 13, 1.
3. Management of stable angina pectoris: Recommendations of the Task Force of the European Society of Cardiology. Eur. Heart J. 1997, 18, 394.
4. A. Markham, G. L. Plosker, K. L. Goa,. Nicorandil: an updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000, 60, 955.
5. D. Simpson, K. Wellington,. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs 2004, 64, 1941.
6. A. M. Frydman, P. Chapelle, H. Diekmann, R. Bruno, J. J. Thebault, J. Bouthier, H. Caplain, W. Ungethuem, C. Gaillard, A. Le Liboux,. Pharmacokinetics of nicorandil. Am. J. Cardiol. 1989, 63, 25 J.
7. K. Sakai, K. Saito,. Comparison of the potentiating effects of nicorandil and its denitrated metabolite (SG-86) on the adenosine-induced vasodepression in rats. Fundam. Clin. Pharmacol. 1998, 12, 492.
8. K. Sakai, K. Saito,. Nicorandil, its denitrated metabolite, SG-86 and naturally occurring vasodilators synergistically interact on adenosine-induced vasodepression in rats: special reference to adrenomedullin. Fundam. Clin. Pharmacol. 1999, 13, 27.
9. U. S. Food and Drug Administration. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, 2003.
10. T. Ishizaki, K. Chiba, T. Suganuma, T. Sasaki, H. Kamiyama, H. Nakano,. Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. J. Pharm. Sci. 1984, 73, 494.
11. Y. Gomita, K. Furuno, K. Eto, T. Fukuda, Y. Araki,. Rapid and simple determination of nicorandil in rat plasma using a solid-phase extraction column. J. Chromatogr. 1990, 528, 509.
12. M. Tanikawa, M. Uzu, Y. Ohsawa, M. Fukushima,. Sensitive method for determination of nicorandil in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 1993, 617, 163.
13. A. Ojha, A. Pargal,. Determination of nicorandil concentrations in human plasma using liquid chromatography. J. Pharm. Biomed. Anal. 1999, 21, 175.
14. S. Andrensek, A. Smidovnik, A. Pecavar, M. Prosek,. Routine and sensitive method for determination of nicorandil in human plasma developed for liquid chromatography with ultraviolet and mass spectrometric detection. J. Chromatogr. B 1999, 735, 103.
15. J. Bhatt, A. Jangid, B. Shah, R. Shetty, S. Kambli, G. Subbaiah, S. Singh,. Rapid and sensitive liquid chromatography-tandem mass spectrometry method for the estimation of nicorandil in human plasma. Biomed. Chromatogr. 2006, 20, 864.
16. U. S. Food, and, Drug Administration,. FDA Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, 2001.